Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination

dc.contributorUniversidade Estadual de Maringá (UEM)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2018-11-26T17:13:49Z
dc.date.available2018-11-26T17:13:49Z
dc.date.created2018-11-26T17:13:49Z
dc.date.issued2016-12-01
dc.identifierJournal Of Microbiology Immunology And Infection. Taipei: Elsevier Taiwan, v. 49, n. 6, p. 980-983, 2016.
dc.identifier1684-1182
dc.identifierhttp://hdl.handle.net/11449/162237
dc.identifier10.1016/j.jmii.2015.08.025
dc.identifierWOS:000389596000022
dc.identifierWOS000389596000022.pdf
dc.description.abstractWe report the in vitro drugs interaction by the resazurin drugs combination micro-titer assay (REDCA) of amoxicillin (AMO)/clavulanate (CLAV) with isoniazid (INH), ethambutol (EMB), and rifampicin (RIF) against susceptible and resistant Mycobacterium tuberculosis isolates. The addition of AMO/CLAV to classical antituberculosis drugs should be explored as a promising alternative for the treatment of resistant tuberculosis (TB). Copyright (C) 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationJournal Of Microbiology Immunology And Infection
dc.relation0,789
dc.rightsAcesso aberto
dc.sourceWeb of Science
dc.subjectamoxicillin/clavulanate
dc.subjectcheckerboard
dc.subjectMycobacterium tuberculosis
dc.subjectsynergism
dc.subjecttuberculosis
dc.titleAnti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución